Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

28.82EUR
24 Feb 2017
Change (% chg)

€0.00 (+0.00%)
Prev Close
€28.82
Open
€28.99
Day's High
€29.30
Day's Low
€28.82
Volume
3,911
Avg. Vol
5,257
52-wk High
€44.95
52-wk Low
€24.00

ALCAR.PA

Chart for ALCAR.PA

About

Carmat SAS is a France-based Company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The Company formed a network of partnerships with hospitals and various scientific... (more)

Overall

Beta: 1.00
Market Cap(Mil.): €170.82
Shares Outstanding(Mil.): 5.93
Dividend: --
Yield (%): --

Financials

  ALCAR.PA Industry Sector
P/E (TTM): -- 34.59 29.63
EPS (TTM): -3.78 -- --
ROI: -72.76 12.50 12.96
ROE: -168.95 14.56 14.11

BRIEF-Carmat FY net loss widens to 23 million euros

* Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016

Feb 14 2017

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implantations.

Feb 06 2017

Carmat withdraws initial request to resume artificial heart implants

Feb 6 Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implants.

Feb 06 2017

Carmat shares slump after France halts heart implants

PARIS Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

Dec 01 2016

French drugs agency suspends new Carmat artificial heart implants

PARIS France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

Nov 30 2016

BRIEF-Carmat H1 net loss widens to EUR 10.2 mln

* H1 total operating income 96,827 euros ($108,901) vs 2,854 euros year ago

Sep 08 2016

BRIEF-Carmat announces departure of CEO Marcello Conviti

* Carmat announces the departure of CEO Marcello Conviti Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 01 2016

BRIEF-Stéphane Piat has been appointed CEO of Carmat

* Stéphane Piat, previously division vice president of Abbott in California, has been appointed CEO of Carmat

Sep 01 2016

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Aug 30 2016

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS, Aug 30 Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Aug 30 2016

More From Around the Web

Earnings vs. Estimates